ZeJing Pharmaceuticals: Approval Notice for Clinical Trials of Injection ZG006 Combined with PD-1/PD-L1 Immune Checkpoint Inhibitors and Chemotherapy.

Zhijing Pharmaceutical announced that the company has recently received the Approval Notice for Drug Clinical Trial issued by the National Medical Products Administration. The clinical trial of the injectable ZG006 combined with PD-1/PD-L1 immune checkpoint inhibitors and chemotherapy for small cell lung cancer has been approved.